SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Sonoma Pharmaceuticals, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.12+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $4.31M
- P/E (TTM)
- –
- Dividend yield
- –
Sonoma Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q1 26 | Q1 25 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | Q2 22 | Q1 22 | Q3 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $4.02M | $3.39M | $3.33M | $1.67M | $2.94M | $3.33M | $2.96M | $1.85M | $2.90M | $3.74M | $3.68M | – | 100.0% | +18.4% |
| Human Care [Member] | – | – | – | – | – | – | – | – | – | – | – | $3.53M | – | – |
| Animal Care [Member] | – | – | – | – | – | – | – | – | – | – | – | $1.36M | – | – |
| Other Sales [Member] | – | – | – | – | – | – | – | – | – | – | – | $45.00K | – | – |
| Service [Member] | – | – | $99.00K | $95.00K | $75.00K | $147.00K | $1.03M | $75.00K | $69.00K | $148.00K | $157.00K | – | – | – |
By region
From the segment and revenue-disaggregation notes of Sonoma Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.